Minor
Multisite Dose-finding and Expansion Study of WTX-330 · Selected Advanced or Metastatic Solid Tumors or Lymphoma
Trial completed
Also in this update: Final enrollment: 24 participants (planned 100); Primary completion date changed from estimate of Aug 2028 to Apr 23, 2026
Werewolf Therapeutics, Inc.Phase 1/2 NCT06939283 Registry history of NCT06939283 on ClinicalTrials.gov (opens the registry)